Halozyme Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Halozyme Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- HALO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001159036
Board of directors
-
Akiko Moni Miyashita · DirectorSince 2023
-
Barbara Gayle Duncan · DirectorSince 2023
-
Bernadette Connaughton · DirectorSince 2023
-
Connie Matsui · DirectorSince 2023
-
Dannielle Appelhans · DirectorSince 2026
-
Helen Torley · Director · PRESIDENT AND CEOSince 2023
-
James M. Daly · DirectorSince 2023
-
James Paul Lang · DirectorSince 2025
-
Jean-Pierre Bizzari · DirectorSince 2023
-
Jeffrey William Henderson · DirectorSince 2023
-
Mahesh Krishnan · DirectorSince 2024
-
Matthew L. Posard · DirectorSince 2023
Chief executives
Helen Torley
· PRESIDENT AND CEO
Dates unknown
Board connections
9 of this board's directors also sit on 17 other boards.
- via James M. Daly
- via Jean-Pierre Bizzari
- via Jean-Pierre Bizzari
- via Connie Matsui
- via Barbara Gayle Duncan
- via Akiko Moni Miyashita
- via Jeffrey William Henderson
- via James Paul Lang
- via James M. Daly
- via Bernadette Connaughton
- via Jeffrey William Henderson
- via James M. Daly
- via Matthew L. Posard
- via James Paul Lang
- via Barbara Gayle Duncan
- via Jeffrey William Henderson
- via Connie Matsui
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $45,665,280
- 103 sales by 5 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 16, 2026 | Matthew L. Posard Director | Open-market sale | −3,100 | $106.13 | $329,009 |
| Sep 16, 2026 | Matthew L. Posard Director | Open-market sale | −3,000 | $106.83 | $320,484 |
| Sep 16, 2026 | Matthew L. Posard Director | Open-market sale | −8,896 | $108.04 | $961,124 |
| Sep 16, 2026 | Matthew L. Posard Director | Open-market sale | −4,000 | $108.99 | $435,964 |
| Sep 11, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 11, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −15,492 | $107.15 | $1,660,030 |
| Sep 11, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −4,508 | $107.55 | $484,826 |
| Sep 10, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 10, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −14,588 | $107.01 | $1,561,091 |
| Sep 10, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −5,412 | $107.58 | $582,228 |
| Sep 9, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Option exercise | +20,000 | $18.41 | $368,200 |
| Sep 9, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −13,304 | $107.22 | $1,426,481 |
| Sep 9, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −6,596 | $107.82 | $711,187 |
| Sep 9, 2026 | Helen Torley Director, Officer (PRESIDENT AND CEO) | Open-market sale | −100 | $108.67 | $10,867 |
| Sep 1, 2026 | Dannielle Appelhans Director | Grant or award | +1,161 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.